| 摘要 |
<p>Disclosed are: a therapeutic agent, a kit and a treatment method for undifferentiated-type of gastric cancer; and a pharmaceutical composition, a kit and a treatment method which are more effective on a living body having at least one cell selected from the group consisting of a cell over-expressing FGFR2 and a cell expressing a FGFR2 mutant. A combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is more effective on undifferentiated-type of gastric cancer. The combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is more effective on a living body having at least one cell selected from the group consisting of a cell over-expressing FGFR2 and a cell expressing a FGFR2 mutant.</p> |
